Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

PD-1 regulation in immune homeostasis and immunotherapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Regulatory mechanisms of PD-1/PD-L1 in cancers

Correction: New Insights into Epigenetic Regulation of Resistance to PD-1/PD-L1 Blockade Cancer Immunotherapy: Mechanisms and Therapeutic Opportunities.

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Regulation of PD-L1 expression in the tumor microenvironment

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

A snapshot of the PD-1/PD-L1 pathway

Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Application of PD-1 Blockade in Cancer Immunotherapy

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy